{"id":"alefacept","rwe":[{"pmid":"41754879","year":"2026","title":"Biological Treatment of Psoriasis-Data So Far.","finding":"","journal":"Pharmaceuticals (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41409530","year":"2025","title":"Immune Cell-Targeting Biologics for Alopecia Areata: A New Paradigm in Precision Medicine.","finding":"","journal":"Skin appendage disorders","studyType":"Clinical Study"},{"pmid":"41386525","year":"2026","title":"Adult-onset type 1 diabetes: early detection, differential diagnosis, and emerging disease-modifying therapies.","finding":"","journal":"Diabetes research and clinical practice","studyType":"Clinical Study"},{"pmid":"40654217","year":"2024","title":"Severe Relapsing Hailey-Hailey Disease Displaying a Durable Complete Response to Hydroxyurea.","finding":"","journal":"Acta dermatovenerologica Croatica : ADC","studyType":"Clinical Study"},{"pmid":"40487626","year":"2025","title":"Immunosuppressive agents in diabetes treatment: Hope or despair?","finding":"","journal":"World journal of diabetes","studyType":"Clinical Study"}],"tags":[{"label":"CD2-directed LFA-3/Fc Fusion Protein","category":"class"},{"label":"Monoclonal Antibody","category":"modality"},{"label":"T-cell surface antigen CD2","category":"target"},{"label":"CD2","category":"gene"},{"label":"L04AA15","category":"atc"},{"label":"Active","category":"status"},{"label":"Plaque psoriasis","category":"indication"},{"label":"Astellas","category":"company"},{"label":"Approved 2000s","category":"decade"},{"label":"Dermatologic Agents","category":"pharmacology"},{"label":"Immunologic Factors","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":270.311,"date":"","count":50,"signal":"Neurologic neglect syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 50 times (LLR=270)"},{"llr":266.535,"date":"","count":50,"signal":"Carotid artery thrombosis","source":"DrugCentral FAERS","actionTaken":"Reported 50 times (LLR=267)"},{"llr":254.568,"date":"","count":63,"signal":"Skin haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 63 times (LLR=255)"},{"llr":238.401,"date":"","count":48,"signal":"Adjustment disorder","source":"DrugCentral FAERS","actionTaken":"Reported 48 times (LLR=238)"},{"llr":229.286,"date":"","count":64,"signal":"Sneezing","source":"DrugCentral FAERS","actionTaken":"Reported 64 times (LLR=229)"},{"llr":228.201,"date":"","count":50,"signal":"Personality disorder","source":"DrugCentral FAERS","actionTaken":"Reported 50 times (LLR=228)"},{"llr":225.783,"date":"","count":63,"signal":"Respiratory tract congestion","source":"DrugCentral FAERS","actionTaken":"Reported 63 times (LLR=226)"},{"llr":223.838,"date":"","count":63,"signal":"Sinus congestion","source":"DrugCentral FAERS","actionTaken":"Reported 63 times (LLR=224)"},{"llr":209.024,"date":"","count":63,"signal":"Sinus disorder","source":"DrugCentral FAERS","actionTaken":"Reported 63 times (LLR=209)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Astellas Pharma","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ALEFACEPT","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:29:07.063322+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Alefacept","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:29:15.107241+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:29:13.729645+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALEFACEPT","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:29:14.527772+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: T-cell surface antigen CD2 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:29:15.106875+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201571/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:29:14.998998+00:00"}},"allNames":"amevive","offLabel":[],"synonyms":["alefacept","BG9712","LFA3TIP","BG9273","amevive"],"timeline":[{"date":"2003-01-30","type":"positive","source":"DrugCentral","milestone":"FDA approval (Astellas)"}],"aiSummary":"Amevive (Alefacept) is a CD2-directed LFA-3/Fc Fusion Protein developed by Astellas, targeting T-cell surface antigen CD2. It is a small molecule drug class, FDA-approved in 2003 for the treatment of plaque psoriasis. Amevive works by binding to CD2 on T-cells, leading to their depletion and subsequent reduction in inflammation. The commercial status of Amevive is patented, and it is currently owned by Astellas. Key safety considerations include potential infections and allergic reactions.","brandName":"Amevive","ecosystem":[{"indication":"Plaque psoriasis","otherDrugs":[{"name":"adalimumab","slug":"adalimumab","company":"Abbvie Inc"},{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"apremilast","slug":"apremilast","company":"Celgene Corp"}],"globalPrevalence":125000000}],"mechanism":{"target":"T-cell surface antigen CD2","novelty":"Follow-on","targets":[{"gene":"CD2","source":"DrugCentral","target":"T-cell surface antigen CD2","protein":"T-cell surface antigen CD2"}],"moaClass":"CD2-directed Antibody Interactions","modality":"Monoclonal Antibody","drugClass":"CD2-directed LFA-3/Fc Fusion Protein","explanation":"","oneSentence":"","technicalDetail":"Amevive is a CD2-directed LFA-3/Fc Fusion Protein that binds to CD2 on T-cells, leading to their depletion through apoptosis and subsequent reduction in inflammation."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Alefacept","title":"Alefacept","extract":"Alefacept is a genetically engineered immunosuppressive drug. It was sold under the brand name Amevive in Canada, the United States, Israel, Switzerland and Australia. In 2011, the manufacturers made a decision to cease promotion, manufacturing, distribution and sales of Amevive during a supply disruption. According to Astellas Pharma US, Inc., the decision to cease Amevive sales was neither the result of any specific safety concern nor the result of any FDA-mandated or voluntary product recall. On the other hand, usage of Amevive was associated with a certain risk of development systemic diseases such as malignancies. This drug was never approved for the European drug market."},"commercial":{"launchDate":"2003","_launchSource":"DrugCentral (FDA 2003-01-30, ASTELLAS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5088","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ALEFACEPT","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALEFACEPT","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Alefacept","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T08:35:23.809970","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:29:16.884148+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"muromonab-CD3","drugSlug":"muromonab-cd3","fdaApproval":"1992-09-14","relationship":"same-class"},{"drugName":"mycophenolic acid","drugSlug":"mycophenolic-acid","fdaApproval":"2004-02-27","relationship":"same-class"},{"drugName":"sirolimus","drugSlug":"sirolimus","fdaApproval":"1999-09-15","patentExpiry":"Oct 28, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"leflunomide","drugSlug":"leflunomide","fdaApproval":"1998-09-10","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"everolimus","drugSlug":"everolimus","fdaApproval":"2009-03-30","patentExpiry":"May 1, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"efalizumab","drugSlug":"efalizumab","fdaApproval":"2003-10-27","relationship":"same-class"},{"drugName":"natalizumab","drugSlug":"natalizumab","fdaApproval":"2004-11-23","relationship":"same-class"},{"drugName":"abatacept","drugSlug":"abatacept","fdaApproval":"2005-12-23","relationship":"same-class"},{"drugName":"eculizumab","drugSlug":"eculizumab","fdaApproval":"2007-03-16","relationship":"same-class"},{"drugName":"belimumab","drugSlug":"belimumab","fdaApproval":"2011-03-09","relationship":"same-class"},{"drugName":"fingolimod","drugSlug":"fingolimod","fdaApproval":"2010-09-21","patentExpiry":"Sep 30, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"belatacept","drugSlug":"belatacept","fdaApproval":"2011-06-15","relationship":"same-class"},{"drugName":"tofacitinib","drugSlug":"tofacitinib","fdaApproval":"2012-11-06","patentExpiry":"Sep 14, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"teriflunomide","drugSlug":"teriflunomide","fdaApproval":"2012-09-12","patentExpiry":"Sep 14, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"apremilast","drugSlug":"apremilast","fdaApproval":"2014-03-21","patentExpiry":"Nov 29, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"vedolizumab","drugSlug":"vedolizumab","fdaApproval":"2014-05-20","relationship":"same-class"},{"drugName":"alemtuzumab","drugSlug":"alemtuzumab","fdaApproval":"2001-05-07","relationship":"same-class"},{"drugName":"ocrelizumab","drugSlug":"ocrelizumab","fdaApproval":"2017-03-28","relationship":"same-class"},{"drugName":"baricitinib","drugSlug":"baricitinib","fdaApproval":"2018-05-31","patentExpiry":"Nov 30, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ozanimod","drugSlug":"ozanimod","fdaApproval":"2020-03-25","patentExpiry":"Sep 30, 2038","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"alefacept","indications":{"approved":[{"name":"Plaque psoriasis","source":"DrugCentral","snomedId":200965009,"regulator":"FDA","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"muromonab-cd3","brandName":"muromonab-CD3","genericName":"muromonab-CD3","approvalYear":"1992","relationship":"same-class"},{"drugId":"mycophenolic-acid","brandName":"mycophenolic acid","genericName":"mycophenolic acid","approvalYear":"2004","relationship":"same-class"},{"drugId":"sirolimus","brandName":"sirolimus","genericName":"sirolimus","approvalYear":"1999","relationship":"same-class"},{"drugId":"leflunomide","brandName":"leflunomide","genericName":"leflunomide","approvalYear":"1998","relationship":"same-class"},{"drugId":"everolimus","brandName":"everolimus","genericName":"everolimus","approvalYear":"2009","relationship":"same-class"},{"drugId":"efalizumab","brandName":"efalizumab","genericName":"efalizumab","approvalYear":"2003","relationship":"same-class"},{"drugId":"natalizumab","brandName":"natalizumab","genericName":"natalizumab","approvalYear":"2004","relationship":"same-class"},{"drugId":"abatacept","brandName":"abatacept","genericName":"abatacept","approvalYear":"2005","relationship":"same-class"},{"drugId":"eculizumab","brandName":"eculizumab","genericName":"eculizumab","approvalYear":"2007","relationship":"same-class"},{"drugId":"belimumab","brandName":"belimumab","genericName":"belimumab","approvalYear":"2011","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00233662","phase":"PHASE3","title":"Safety and Tolerability of Repeat Courses of IM Alefacept","status":"COMPLETED","sponsor":"Biogen","startDate":"2002-12-01","conditions":["Chronic Plaque Psoriasis"],"enrollment":400,"completionDate":"2005-12-01"},{"nctId":"NCT00438802","phase":"PHASE1","title":"Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2006-03","conditions":["Lymphoma"],"enrollment":23,"completionDate":"2019-07-25"},{"nctId":"NCT00167102","phase":"NA","title":"Alefacept in Patients With Severe Scalp Alopecia Areata","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2005-07","conditions":["Alopecia Areata"],"enrollment":45,"completionDate":"2008-02"},{"nctId":"NCT00678470","phase":"NA","title":"Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2007-09","conditions":["Moderate to Severe Psoriasis"],"enrollment":18,"completionDate":"2011-06"},{"nctId":"NCT00655564","phase":"PHASE4","title":"Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis","status":"COMPLETED","sponsor":"Wake Forest University","startDate":"2008-05","conditions":["Psoriasis"],"enrollment":15,"completionDate":"2010-01"},{"nctId":"NCT00815633","phase":"PHASE4","title":"A Pilot Study of Alefacept for the Treatment of Pityriasis Rubra Pilaris","status":"TERMINATED","sponsor":"Joshua Zeichner","startDate":"2008-12","conditions":["Pityriasis Rubra Pilaris"],"enrollment":1,"completionDate":"2010-03"},{"nctId":"NCT01267643","phase":"PHASE1","title":"Alefacept in Patients With Relapsed/Refractory Aplastic Anemia","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2011-05","conditions":["Aplastic Anemia"],"enrollment":4,"completionDate":"2013-04-16"},{"nctId":"NCT01319851","phase":"NA","title":"Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation","status":"TERMINATED","sponsor":"Emory University","startDate":"2010-09","conditions":["Thalassemia","Sickle Cell Disease","Glanzmann Thrombasthenia","Wiskott-Aldrich Syndrome","Chronic-granulomatous Disease","Severe Congenital Neutropenia","Leukocyte Adhesion Deficiency","Schwachman-Diamond Syndrome","Diamond-Blackfan Anemia","Fanconi Anemia","Dyskeratosis-congenita","Chediak-Higashi Syndrome","Severe Aplastic Anemia"],"enrollment":3,"completionDate":"2013-09"},{"nctId":"NCT00965458","phase":"PHASE2","title":"Inducing Remission in Type 1 Diabetes With Alefacept","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-03","conditions":["New-onset Type 1 Diabetes Mellitus"],"enrollment":49,"completionDate":"2014-04"},{"nctId":"NCT00617604","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-12","conditions":["De Novo Kidney Transplantation"],"enrollment":218,"completionDate":"2009-09"},{"nctId":"NCT00543569","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-02","conditions":["Kidney Transplantation"],"enrollment":323,"completionDate":"2011-02"},{"nctId":"NCT00361413","phase":"PHASE3","title":"Alefacept for Prevention of Graft Versus Host Disease (GVHD)","status":"TERMINATED","sponsor":"Hadassah Medical Organization","startDate":"2006-06","conditions":["Graft Versus Host Disease"],"enrollment":26,"completionDate":"2013-12"},{"nctId":"NCT00397332","phase":"PHASE1,PHASE2","title":"Alefacept for Chronic Graft Versus Host Disease","status":"COMPLETED","sponsor":"Hadassah Medical Organization","startDate":"2006-10","conditions":["Resistant Chronic GVHD"],"enrollment":20,"completionDate":"2013-07"},{"nctId":"NCT00692172","phase":"PHASE3","title":"Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2001-12","conditions":["Psoriasis"],"enrollment":175,"completionDate":"2004-11"},{"nctId":"NCT00659412","phase":"PHASE2","title":"A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2003-09","conditions":["Psoriatic Arthritis"],"enrollment":185,"completionDate":"2005-03"},{"nctId":"NCT00168753","phase":"PHASE4","title":"Community Based Trial for AMEVIVE®","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-07","conditions":["Moderate to Severe Chronic Plaque Psoriasis"],"enrollment":114,"completionDate":"2005-03"},{"nctId":"NCT00673556","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2003-10","conditions":["Chronic Plaque Psoriasis"],"enrollment":195,"completionDate":"2005-05"},{"nctId":"NCT00674063","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2003-07","conditions":["Chronic Plaque Psoriasis"],"enrollment":78,"completionDate":"2004-04"},{"nctId":"NCT00808223","phase":"PHASE2","title":"Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-04","conditions":["Psoriasis"],"enrollment":30,"completionDate":"2012-02"},{"nctId":"NCT00342862","phase":"","title":"AMEVIVE® Pregnancy Registry","status":"TERMINATED","sponsor":"Astellas Pharma Inc","startDate":"2003-12","conditions":["Pregnancy"],"enrollment":3,"completionDate":"2011-12"},{"nctId":"NCT00454701","phase":"","title":"Assessment and Tracking of Long-term Alefacept Safety","status":"TERMINATED","sponsor":"Astellas Pharma Inc","startDate":"2003-06","conditions":["Psoriasis"],"enrollment":1897,"completionDate":"2012-02"},{"nctId":"NCT01226420","phase":"PHASE2","title":"Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2010-10","conditions":["Chronic Graft-versus-host Disease"],"enrollment":6,"completionDate":"2012-08"},{"nctId":"NCT01163799","phase":"PHASE1","title":"A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2010-07","conditions":["Transplant; Failure, Kidney"],"enrollment":9,"completionDate":"2012-08"},{"nctId":"NCT00795353","phase":"","title":"Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"TERMINATED","sponsor":"Astellas Pharma Inc","startDate":"2008-07","conditions":["Chronic Plaque Psoriasis"],"enrollment":64,"completionDate":"2011-01"},{"nctId":"NCT00653822","phase":"PHASE1","title":"A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-03","conditions":["Pharmacokinetics of Alefacept"],"enrollment":75,"completionDate":"2008-07"},{"nctId":"NCT00953329","phase":"PHASE4","title":"Alefacept in Subjects With Chronic Plaque Psoriasis Who Failed to Respond to Anti-TNF Therapy","status":"TERMINATED","sponsor":"John Murray","startDate":"2008-02","conditions":["Chronic Plaque Psoriasis"],"enrollment":1,"completionDate":"2008-12"},{"nctId":"NCT00658606","phase":"PHASE4","title":"Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-10","conditions":["Plaque Psoriasis"],"enrollment":98,"completionDate":"2009-12"},{"nctId":"NCT01433770","phase":"NA","title":"Alefacept in Kidney Transplant Recipients","status":"WITHDRAWN","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2011-10","conditions":["Kidney Transplantation"],"enrollment":0,"completionDate":"2014-10"},{"nctId":"NCT00493324","phase":"PHASE4","title":"Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-07","conditions":["Chronic Plaque Psoriasis"],"enrollment":43,"completionDate":"2008-07"},{"nctId":"NCT00371774","phase":"","title":"Amevive Wisdom Acquired From Real-Time Evidence (A.W.A.R.E™) Program","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2005-06","conditions":["Plaque Psoriasis"],"enrollment":426,"completionDate":"2008-05"},{"nctId":"NCT00832585","phase":"PHASE4","title":"Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2008-01","conditions":["Atopic Dermatitis"],"enrollment":5,"completionDate":"2009-10"},{"nctId":"NCT00407342","phase":"NA","title":"Alefacept (Amevive) With or Without Narrowband UVB Treatment in Patients With Psoriasis.","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2004-02","conditions":["Psoriasis"],"enrollment":14,"completionDate":"2004-09"},{"nctId":"NCT00135733","phase":"PHASE2","title":"A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2004-04","conditions":["Lichen Planus"],"enrollment":13,"completionDate":"2004-12"},{"nctId":"NCT00143806","phase":"PHASE2","title":"Transitioning From Cyclosporine to Alefacept in Psoriasis","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2003-10","conditions":["Psoriasis"],"enrollment":13,"completionDate":"2007-05"},{"nctId":"NCT00794807","phase":"PHASE4","title":"Safety and Tolerability of Repeat Courses of IM Alefacept","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2004-02","conditions":["Chronic Plaque Psoriasis"],"enrollment":20,"completionDate":"2005-12"},{"nctId":"NCT00150982","phase":"PHASE2","title":"Alefacept Mechanism of Action in Psoriasis","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2003-09","conditions":["Psoriasis"],"enrollment":9,"completionDate":"2005-02"},{"nctId":"NCT00376129","phase":"PHASE2","title":"Open-Label,Singel Center Study of Alefacept in Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2006-01","conditions":["Atopic Dermatitis"],"enrollment":10,"completionDate":"2007-01"},{"nctId":"NCT00422617","phase":"NA","title":"Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients","status":"COMPLETED","sponsor":"Uni-Pharma","startDate":"2005-01","conditions":["Chronic Plaque Psoriasis"],"enrollment":40,"completionDate":"2005-11"},{"nctId":"NCT00301002","phase":"PHASE2","title":"Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar Pustulosis","status":"COMPLETED","sponsor":"The Guenther Dermatology Research Centre","startDate":"2005-06","conditions":["Psoriasis","Palmoplantaris Pustulosis","Pustular Psoriasis of Palms and Soles","Pustulosis Palmaris et Plantaris","Pustulosis of Palms and Soles"],"enrollment":15,"completionDate":"2006-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"MMSL":"17114","NDDF":"009880","UNII":"ELK3V90G6C","VANDF":"4021373","INN_ID":"8059","RXNORM":"299635","UMLSCUI":"C0962603","chemblId":"CHEMBL1201571","ChEMBL_ID":"CHEMBL1201571","KEGG_DRUG":"D02800","DRUGBANK_ID":"DB00092","SNOMEDCT_US":"398691006","IUPHAR_LIGAND_ID":"6787","MESH_DESCRIPTOR_UI":"D000077944"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2003-","companyName":"Astellas","relationship":"Original Developer"}],"publicationCount":392,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"L04AA15","allCodes":["L04AA15"]},"biosimilarFilings":[],"originalDeveloper":"Astellas","recentPublications":[{"date":"2026 Feb 21","pmid":"41754879","title":"Biological Treatment of Psoriasis-Data So Far.","journal":"Pharmaceuticals (Basel, Switzerland)"},{"date":"2025 Nov 10","pmid":"41409530","title":"Immune Cell-Targeting Biologics for Alopecia Areata: A New Paradigm in Precision Medicine.","journal":"Skin appendage disorders"},{"date":"2026 Jan","pmid":"41386525","title":"Adult-onset type 1 diabetes: early detection, differential diagnosis, and emerging disease-modifying therapies.","journal":"Diabetes research and clinical practice"},{"date":"2024 Nov","pmid":"40654217","title":"Severe Relapsing Hailey-Hailey Disease Displaying a Durable Complete Response to Hydroxyurea.","journal":"Acta dermatovenerologica Croatica : ADC"},{"date":"2025 May 15","pmid":"40487626","title":"Immunosuppressive agents in diabetes treatment: Hope or despair?","journal":"World journal of diabetes"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Astellas Pharma","companyId":"astellas","modality":"Recombinant protein","firstApprovalDate":"2003","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:29:16.884148+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}